查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844149

攝護腺癌核醫診斷市場（依放射性藥物、模式、最終使用者和適應症分類）－2025-2032年全球預測

Prostate Cancer Nuclear Medicine Diagnostics Market by Radiopharmaceutical, Modality, End User, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，攝護腺癌核醫診斷市場規模將達到 31.2 億美元，複合年成長率為 13.19%。

主要市場統計數據
基準年 2024 11.5億美元
預計年份：2025年 13.1億美元
預測年份：2032年 31.2億美元
複合年成長率 (%) 13.19%

臨床、技術和商業性力量的融合正在重塑用於前列腺癌治療的核醫學診斷。

由於分子影像技術的進步、臨床診療途徑的不斷發展以及跨學科合作的日益密切，前列腺癌核醫學診斷的臨床和技術格局正在發生顯著變化。過去以傳統影像學方法為主的診斷方法，如今正逐步引入更靈敏的放射性藥物和混合影像平台，以實現更精準的定位、分期和復發檢測。因此，臨床醫生和醫療系統正在重新評估診斷流程，以最佳化患者分層和治療決策。

在臨床應用的同時，對影像基礎設施、放射化學能力和人才隊伍建設的投資正在重塑醫療服務提供者的營運考量。放射性藥物的創新與掃描儀硬體和軟體的改進相輔相成，提高了影像品質和通量，從而能夠更可靠地檢測低豐度疾病。同時，包括生物製藥公司、設備製造商和學術中心在內的相關人員正在累積臨床效用和健康結果方面的證據，這些證據反映在與支付方的溝通以及治療路徑的整合中。

展望未來，法律規範、報銷政策和供應鏈韌性之間的相互作用將決定這些創新成果轉化為日常實踐的速度。對於那些希望影響臨床實踐並創造價值的機構而言，策略夥伴關係和數據主導的方法正變得至關重要。在此背景下，了解推動技術應用的技術、臨床和商業性因素，對於希望引領前列腺癌核醫學診斷下一階段發展的管理者、臨床醫生和投資者至關重要。

探討能夠提高診斷準確性並重新定義前列腺癌影像通道的關鍵技術和臨床曲折點

近年來，核子醫學在前列腺癌檢測領域發生了變革性變化，正在改變診斷流程和相關人員的預期。針對前列腺特異性膜抗原（PSMA）的顯影劑的成熟，拓寬了臨床醫師的選擇範圍，提高了病灶檢出率，降低了疾病負荷，並促使人們重新評估影像學檢查的適應症。放射化學的同步發展使<sup>18</sup>F標記的顯影劑在操作上比基於發生器的同位素更具優勢，而新型同位素的出現則進一步豐富了診斷和潛在治療套件。

同時，成像硬體和分析平台也取得了長足進展。飛行時間子斷層掃描（TOF-PET）和數位正子斷層掃描（D-PET）提高了空間解析度和靈敏度，不僅增強了診斷的可靠性，還縮短了掃描時間並降低了輻射劑量。雖然混合式SPECT/CT在某些適應症中仍然有效，但整體發展趨勢傾向於以PET為中心的工作流程，因為臨床證據表明，PET能夠提高診斷產量。定量影像指標和人工智慧輔助後處理的整合正在逐步規​​範報告流程，並減少閱片者之間的差異，從而加強影像輸出與臨床決策之間的連結。

在政策和商業領域，報銷管道正隨著臨床證據的不斷累積而演變，但不同支付方和地區之間存在差異。隨著製造商、放射藥物供應商和醫療服務提供者著手解決物流、低溫運輸管理和生產規模化等問題，供應鏈因素的重要性日益凸顯。總體而言，這些轉變反映了精準診斷的廣泛趨勢，即整合影像學檢查方式、藥物選擇和臨床意圖，為前列腺癌的個人化治療提供可操作的資訊。

新的貿易措施如何推動核醫學診斷領域的策略供應鏈調整、生產在地化和採購創新

貿易當局實施的新關稅對支撐核醫學診斷的複雜全球供應鏈產生了重大影響。對關鍵組件、試劑和成品放射性藥物徵收的關稅會影響製造商、放射性藥物工廠和影像中心的採購決策。隨著進口關稅的增加，企業面臨更高的到岸成本，被迫重新評估籌資策略，以維持服務的連續性和競爭優勢。

為了應對關稅帶來的成本壓力，企業和醫療系統可能會將生產本地化並加強本地合作。投資國內放射化學品生產能力和區域分銷網路將變得更具吸引力，以此作為對沖貿易摩擦的手段。此外，製造商可能會加快對可在本地生產的替代同位素和標記化學品進行認證的步伐，或減少對受關稅影響的投入品的依賴。這些調整將有助於降低風險，但需要資金、前置作業時間和與監管機構的協調。

在營運層面，影像服務提供者必須應對採購、庫存和合約調整等一系列挑戰。長期合約、供應商多元化以及與學術中心和第三方迴旋加速器營運商的密切合作可以降低成本波動帶來的風險。從策略角度來看，貿易相關的成本轉移也會影響成本效益評估和與支付者的談判。最終，關稅將成為供應鏈重組的催化劑，促使各方採取措施增強供應鏈的韌性，並專注於加強商業、臨床和監管等相關人員之間的協調。

將放射性藥物選擇、成像方式能力、醫療環境屬性和臨床適應症與可操作的診斷策略聯繫起來的精細分割洞察

該報告的洞察揭示了放射性藥物類別、影像方式、醫療環境和臨床適應症之間的差異化動態，從而為部署策略提供基礎。基於放射性藥物，報告研究了<sup>11</sup>C 膽鹼、<sup>18</sup>F DcfpyL、<sup>18</sup>F 氟西克洛韋、<sup>68</sup>Ga PSMA 和新興藥物的市場情況，其中新興藥物包括<sup>18</sup>F PSMA 1007 和<sup>64</sup>Cu PSMA。按影像方式分類，報告研究了 PET 和 SPECT 的市場情況，其中 PET 進一步細分為數位 PET 和 TOF PET，SPECT 則細分為傳統 SPECT 和 SPECT CT。按最終用戶分類，報告研究了學術研究機構、診斷中心和醫院的市場狀況。這種細分突顯了營運規模、臨床複雜性和現場放射化學資源取得的差異，這些差異反過來又會影響技術的採用時間。按適應症分類，報告研究了生化復發檢測、早期分期和治療監測的市場情況。根據這些適應症選擇合適的藥物和治療方式，可以最大限度地提高診斷產量和臨床效用。

了解這些環節如何交織至關重要。例如，高靈敏度PET顯影劑與數位PET掃描儀的結合，在以檢測生化復發為重點的場景中尤其重要，但這種結合需要對影像基礎設施和可靠的放射性藥物供應進行投資。相反，提供綜合腫瘤服務的醫院可以利用院內放射化學資源和策略性供應協議，優先選擇能夠支援分期和治療監測流程的顯影劑和影像方式。學術研究機構在檢驗新顯影劑和完善臨床通訊協定發揮關鍵作用。將臨床問題與合適的顯影劑、影像方式和臨床環境結合，有助於相關人員最佳化診斷流程和資源分配。

從區域觀點影響先進核子醫學診斷技術取得和全球應用的監管、基礎設施和支付方促進因素

區域動態，尤其是法規環境、基礎設施能力和支付框架的差異，對先進核醫學診斷技術的採納和廣泛應用有顯著影響。在美洲，臨床應用主要得益於一流的醫療設施、完善的放射性藥物網路以及對影像結果與治療決策之間關聯證據的日益重視。在歐洲、中東和非洲，情況則較為複雜，一些國家能夠迅速整合先進的PET顯像劑和最新的掃描儀技術，而另一些國家則由於基礎設施和報銷政策的差異而面臨應用受限的問題。在亞太地區，對影像基礎設施的大力投資、訓練有素的專家數量的增加以及戰略性的行業聯盟正在加速技術的普及，但放射性藥物的配送和監管協調等物流問題仍然是需要優先考慮的事項。

為了從區域觀察走向實際行動，相關人員在規劃商業化和市場進入策略時，必須考慮每個區域獨特的有利因素和限制因素。供應鏈設計、監管溝通以及支付方證據的收集都必須根據當地實際情況進行調整。此外，利用區域臨床卓越中心進行價值論證和最佳實踐推廣，可以促進不同醫療保健系統之間更公平的醫療服務取得和一致的醫療服務標準。

開發商、設備供應商、放射藥業和臨床中心之間透過策略競爭與合作，推動臨床檢驗和市場准入。

核子醫學診斷領域的競爭動態反映了專業放射性藥物開發商、影像設備製造商、商業性放射性藥物製造商和學術研究聯盟之間的整合。放射性藥物開發商投資於臨床試驗和生產規模化，以確保臨床應用；影像設備供應商則專注於硬體和軟體創新，以提高靈敏度和易用性。商業性放射性藥物製造商和第三方迴旋加速器營運商的重要性日益凸顯，因為他們提供的分散式生產解決方案降低了不具備現場生產能力的診所的准入門檻。

合作研究和策略聯盟在推動臨床證據和市場進入方面發揮核心作用。研發供應商通常與學術中心合作檢驗臨床終點，或與影像供應商合作最佳化藥物與掃描器的兼容性。同時，診斷中心和醫院開展試驗計畫，以展示工作流程整合、成本影響和病患療效。監管策略和與支付方的溝通仍然是區分企業優劣的關鍵。積極開發可靠的比較證據和健康結果證據的公司，在與保險公司談判保險覆蓋範圍以及將其技術整合到臨床管道方面更具優勢。從商業性角度來看，提供整合藥物供應、影像系統和服務支援的捆綁式解決方案的公司，可以簡化醫療服務提供者的流程，並建立更牢固的客戶關係。

為領導者制定優先行動方案，以加速證據產生、供應鏈韌性、支付方參與、營運準備和推廣應用。

產業領導者若想充分利用攝護腺癌核醫領域的進展，應制定一套協調一致的策略，將臨床證據的產生、供應鏈的韌性、與支付者的互動結合。首先，應優先進行能夠影響決策終點的臨床研究，例如影像技術如何改變行政流程以及最終的患者預後。其次，應投資於靈活的生產和分銷模式，包括與區域迴旋加速器營運商和商業性放射性藥房建立合作關係，以降低貿易和物流中斷的風險。

同時，我們將加快採用已確立臨床效用的先進影像處理硬體和分析技術，並將資本投資與營運培訓計劃相結合，以確保高效利用。我們將積極與支付方和衛生技術評估機構合作，提供反映真實工作流程的實用證據和衛生經濟學分析。我們將與價值鏈上的開發商、影像處理供應商、醫療服務提供者和病患權益倡導組織建立策略聯盟，以製定整合的價值提案，減少實施阻力。最後，我們將制定數位資料策略，以實現長期結果追蹤和真實世界證據的產生。這些能力將支持持續改進、監管互動和商業化工作。這些措施將為臨床影響和永續的商業性績效奠定堅實的基礎。

透過透明的多源研究途徑，結合專家訪談、同儕審查的證據綜合和迭代檢驗，獲得可靠的洞見。

這些研究成果的依據是：結合了對同儕審查文獻、監管指南和公開臨床試驗註冊庫的實證綜述，以及對來自臨床、生產和商業營運領域的專家進行的結構化訪談。主要研究包括與核子醫學從業人員、放射藥劑師和影像操作負責人進行定性討論，以了解實際工作流程中的考慮因素、應用障礙以及技術性能的權衡取捨。次要研究則綜合分析了技術白皮書、共識指南和產品文檔，以揭示各種影像方式的功能和藥物特性。

調查方法結果經過多資訊來源三角檢驗，並透過與方法學家和領域專家反覆磋商加以完善。資料品管包括交叉核對不同來源資料、協調相互矛盾的訊息，並著重於臨床效用終點而非專有商業性指標。研究方法優先考慮方法學的透明度和研究結果的可重複性，以支持臨床領導者、製造商和政策制定者做出可靠的決策。針對證據缺口，分析確定了優先研究方向，並建議了能夠有效填補這些缺口的研究設計。

本文簡要概述了技術創新、營運韌性和主導商業化將如何融合，從而塑造前列腺癌診斷的未來。

放射性藥物、影像硬體和分析技術的進步共同提升了核子醫學診斷在前列腺癌治療中的作用。這些進展能夠更精準地檢測病灶，改善臨床決策，並為診斷與治療計劃的更緊密結合鋪平道路。同時，貿易政策的變化和日益複雜的供應鏈凸顯了戰略韌性和在地化能力的重要性。由此形成了一個快速發展的生態系統，該系統必須將技術創新與切實可行的商業化策略、實證醫學證據的產生以及與支付方的溝通協調起來。

顯然，價值鏈上的相關人員迫切需要將臨床優先事項與營運實際情況和打入市場策略相協調。投資於可靠的臨床檢驗、確保多元化且具有韌性的供應鏈，以及向支付方和醫療服務提供者闡明清晰的價值命題，可以幫助企業加速將診斷創新轉化為改善患者預後的成果。醫療機構間的協作和數據共用將進一步加快技術應用和一致性治療的步伐。最終，在臨床、商業和物流領域進行周密的執行將決定哪些創新技術能夠在前列腺癌診斷領域產生有意義且持久的影響。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將PSMA標靶PET影像技術應用於復發性攝護腺癌的早期檢測與分期
  • 放射性標記小分子療法的進步改善了轉移性去勢抵抗性前列腺癌（mCRPC）靶向放射性核素治療的療效。
  • 推出新一代數位PET/CT掃描儀，以提高前列腺癌診斷的影像解析度和定量準確性
  • 一種新型PSMA標靶放射性核種偶聯物在治療診斷前列腺癌患者的應用：監管核准與商業化
  • 混合型PET/MRI系統的發展旨在減少輻射暴露，同時提高前列腺成像中軟組織表徵的準確性
  • 新興人工智慧演算法在核醫前列腺癌檢查中的自動解讀和預後風險分層的應用
  • 在臨床實務中，個人化劑量測定軟體的應用日益廣泛，旨在最佳化鎦-177放射性配體療法的安全性和有效性。
  • 學術界與製藥公司的合作加速了新型α射線PSMA療法在前列腺癌治療的臨床試驗。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 攝護腺癌核醫診斷劑市場（依放射性藥物分類）

  • 11C Choline
  • 18F DcfpyL
  • 18F Fluciclovine
  • 68Ga Psma
  • 新興代理人
    • 18F Psma 1007
    • 64Cu Psma

第9章 攝護腺癌核醫診斷劑市場（依模式分類）

  • PET
    • 數字PET
    • TOF PET
  • SPECT
    • 常規SPECT
    • SPECT CT

第10章 攝護腺癌核子醫學診斷劑市場（依最終用戶分類）

  • 學術研究機構
  • 診斷中心
  • 醫院

第11章 攝護腺癌核子醫學診斷劑市場（依適應症分類）

  • 生化復發檢測
  • 初始階段
  • 治療監測

第12章 攝護腺癌核子醫學診斷劑市場（按地區分列）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 攝護腺癌核醫診斷劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國前列腺癌核醫診斷劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • GE HealthCare Technologies Inc.
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Cardinal Health, Inc.
    • Bayer AG
    • Lantheus Holdings, Inc.
    • Bracco Imaging SpA
    • Telix Pharmaceuticals Limited
    • Eckert & Ziegler Strahlen-und Medizintechnik AG
    • Isotope Technologies Munich SE
Product Code: MRR-ED54C46E821C

The Prostate Cancer Nuclear Medicine Diagnostics Market is projected to grow by USD 3.12 billion at a CAGR of 13.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.15 billion
Estimated Year [2025] USD 1.31 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 13.19%

A thoughtful orientation to the converging clinical, technical, and commercial forces reshaping nuclear medicine diagnostics for prostate cancer care

The clinical and technological landscape of nuclear medicine diagnostics for prostate cancer is undergoing a significant transformation driven by advances in molecular imaging, evolving clinical pathways, and increasing interdisciplinary collaboration. Historically anchored in conventional imaging modalities, diagnostic practice now incorporates higher-sensitivity radiopharmaceuticals and hybrid imaging platforms that deliver more precise localization, staging, and recurrence detection. As a result, clinicians and health systems are re-evaluating diagnostic algorithms to optimize patient stratification and therapeutic decision-making.

Alongside clinical adoption, investments in imaging infrastructure, radiochemistry capabilities, and workforce training are reshaping operational considerations for providers. Radiopharmaceutical innovation is complemented by improvements in scanner hardware and software that enhance image quality and throughput, enabling more reliable detection of small-volume disease. Simultaneously, stakeholders across biopharma, device manufacturing, and academic centers are generating evidence on clinical utility and health outcomes, which in turn informs payer dialogues and pathway integration.

Looking forward, the interplay between regulatory frameworks, reimbursement policies, and supply chain resilience will determine how rapidly these innovations translate into routine care. Strategic partnerships and data-driven approaches are becoming essential for organizations that aim to influence clinical practice and capture value. In this context, understanding the technical, clinical, and commercial vectors that drive adoption is critical for executives, clinicians, and investors seeking to navigate the next phase of nuclear medicine diagnostics for prostate cancer.

An examination of the pivotal technological and clinical inflection points that are accelerating diagnostic precision and redefining imaging pathways for prostate cancer

Recent years have seen transformative shifts in prostate cancer nuclear medicine that are altering diagnostic pathways and stakeholder expectations. The maturation of prostate-specific membrane antigen-targeted agents has expanded options for clinicians, improving lesion detection at lower disease burdens and prompting reappraisal of imaging indications. Parallel advances in radiochemistry have enabled 18F-labeled agents to offer logistical advantages over generator-based isotopes, while the emergence of novel isotopes broadens the diagnostic and potential theranostic toolkit.

Concurrently, imaging hardware and analytical platforms have progressed. Time-of-flight and digital PET capabilities deliver higher spatial resolution and sensitivity, which not only improve diagnostic confidence but also reduce scan durations and dose requirements. Hybrid SPECT/CT remains relevant for specific indications, yet the overall momentum favors PET-centric workflows where clinical evidence supports incremental diagnostic yield. Integration of quantitative imaging metrics and AI-enabled post-processing is beginning to standardize reporting and reduce inter-reader variability, thereby strengthening the link between imaging outputs and management decisions.

In the policy and commercial arenas, reimbursement pathways are evolving in response to accumulating clinical evidence, though variability persists across payers and geographies. Supply chain considerations have risen to prominence as manufacturers, radiopharmacies, and providers respond to logistics, cold-chain management, and production scalability. Taken together, these shifts reflect a broader movement toward precision diagnostics that align imaging modality, agent selection, and clinical intent to yield actionable information for personalized prostate cancer care.

How new trade measures are prompting strategic supply chain adaptation, production regionalization, and procurement innovation across nuclear medicine diagnostics

The introduction of new tariff measures by trade authorities has material implications for the complex, global supply chains that underpin nuclear medicine diagnostics. Tariffs applied to key components, reagents, and finished radiopharmaceuticals influence procurement decisions across manufacturers, radiopharmacies, and imaging centers. When import duties rise, organizations confront higher landed costs and the need to reassess sourcing strategies to preserve service continuity and competitive positioning.

In response to tariff-driven cost pressures, companies and health systems are likely to pursue greater regionalization of production and strengthened local partnerships. Investments in domestic radiochemistry capacity and regional distribution networks become more attractive as a hedge against trade friction. Moreover, manufacturers may accelerate efforts to qualify alternative isotopes or labeling chemistries that can be produced locally or that rely less on tariff-affected inputs. Such adaptations help mitigate exposure but require capital, lead time, and regulatory coordination.

Operationally, imaging providers must navigate a mix of procurement, inventory, and contractual adjustments. Longer-term contracts, diversified supplier bases, and closer alignment with academic centers or third-party cyclotron operators can reduce vulnerability to cost volatility. From a strategic standpoint, trade-related cost shifts also influence cost-effectiveness assessments and payer negotiations, particularly where higher acquisition costs are not matched by demonstrable reductions in downstream expenditures. Ultimately, tariffs act as a catalyst for supply chain reconfiguration, encouraging resilience-building measures while placing a premium on coordination across commercial, clinical, and regulatory stakeholders.

Granular segmentation insights that connect radiopharmaceutical selection, imaging modality capabilities, care setting attributes, and clinical indication to actionable diagnostic strategies

Segmentation-based insights reveal differentiated dynamics across radiopharmaceutical categories, imaging modalities, care settings, and clinical indications that inform deployment strategies. Based on Radiopharmaceutical, the market is studied across 11C Choline, 18F DcfpyL, 18F Fluciclovine, 68Ga PSMA, and Emerging Agents, with the Emerging Agents further examined across 18F PSMA 1007 and 64Cu PSMA; each agent class exhibits unique production, logistical, and clinical adoption characteristics that affect where and how they are implemented. Based on Modality, the market is studied across PET and SPECT, with PET further divided into Digital PET and Time Of Flight PET and SPECT subdivided into Conventional SPECT and SPECT CT; these distinctions highlight trade-offs between resolution, throughput, and capital requirements that facilities must weigh. Based on End User, the market is studied across Academic Research Institutes, Diagnostic Centers, and Hospitals; this segmentation underscores differences in operational scale, clinical complexity, and access to on-site radiochemistry that shape adoption timelines. Based on Indication, the market is studied across Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring; aligning agent and modality selection to these indications maximizes diagnostic yield and clinical utility.

Understanding how these segments intersect is essential. For example, highly sensitive PET agents paired with digital PET scanners can be particularly impactful in settings focused on biochemical recurrence detection, but such pairings require investment in imaging infrastructure and reliable radiopharmaceutical supply. Conversely, hospitals with integrated oncology services may prioritize agents and modalities that support both staging and treatment monitoring workflows, leveraging in-house radiochemistry or strategic supplier agreements. Academic research institutes play a pivotal role in validating emerging agents and refining clinical protocols, thereby influencing downstream adoption across diagnostic centers and hospitals. By mapping clinical questions to the right combination of agent, modality, and care setting, stakeholders can optimize diagnostic pathways and resource allocation.

Region-specific perspectives on regulatory, infrastructural, and payer drivers that shape access and adoption of advanced nuclear medicine diagnostics globally

Regional dynamics exert a strong influence on the adoption and diffusion of advanced nuclear medicine diagnostics, shaped by differences in regulatory environments, infrastructure capacity, and payer frameworks. In the Americas, clinical uptake has been driven by centers of excellence, an established radiopharmacy network, and a growing emphasis on evidence that links imaging outcomes to therapeutic decision-making; consequently, early adoption clusters often emerge around academic hospitals and specialized cancer centers. Across Europe, Middle East & Africa, the landscape is heterogeneous, with some countries showing rapid integration of advanced PET agents and modern scanner technologies while others face constrained access due to infrastructure or reimbursement variability; collaboration between regional hubs and national health systems plays an important role in expanding access. In the Asia-Pacific region, strong investments in imaging infrastructure, increasing numbers of trained specialists, and strategic industrial partnerships are accelerating adoption, though logistical considerations for radiopharmaceutical distribution and regulatory harmonization remain ongoing priorities.

Transitioning from regional observation to action, stakeholders should consider the unique enablers and constraints of each geography when planning commercialization and access strategies. Supply chain design, regulatory engagement, and payer evidence-generation must be tailored to regional realities. Moreover, leveraging regional centers of clinical excellence to demonstrate value and disseminate best practices can expedite more equitable access and consistent standards of care across diverse healthcare systems.

Strategic competitive and collaborative behaviors among developers, equipment vendors, radiopharmacies, and clinical centers that drive clinical validation and market access

Competitive dynamics within the nuclear medicine diagnostics space reflect a blend of specialized radiopharmaceutical developers, imaging equipment manufacturers, commercial radiopharmacies, and academic research consortia. Radiopharmaceutical developers are investing in clinical trials and manufacturing scale-up to secure clinical uptake, while imaging systems vendors focus on hardware and software innovations that improve sensitivity and usability. Commercial radiopharmacies and third-party cyclotron operators are increasingly important as they provide distributed production solutions that lower barriers to entry for clinics without on-site manufacturing capacity.

Collaborations and strategic alliances are central to advancing both clinical evidence and market access. Developers often partner with academic centers to validate clinical endpoints and with imaging vendors to optimize agent-scanner compatibility. Meanwhile, diagnostic centers and hospitals form pilot programs to demonstrate workflow integration, cost implications, and patient outcomes. Regulatory strategy and payer engagement remain differentiating activities: organizations that proactively generate robust comparative and health outcomes evidence are better positioned to negotiate coverage and embed their technologies into clinical pathways. From a commercial perspective, companies that offer bundled solutions-combining agent supply, imaging systems, and service support-can simplify adoption for providers and create stickier customer relationships.

A prioritized playbook for leaders that aligns evidence generation, supply chain resilience, payer engagement, and operational readiness to accelerate adoption

Industry leaders seeking to capitalize on advances in prostate cancer nuclear medicine should pursue a coherent strategy that aligns clinical evidence generation, supply chain resilience, and payer engagement. First, prioritize clinical studies that address decision-impact endpoints, such as how imaging alters management pathways and downstream patient outcomes; these data are the currency that informs reimbursement and guideline inclusion. Second, invest in flexible manufacturing and distribution models, including partnerships with regional cyclotron operators and commercial radiopharmacies, to reduce exposure to trade and logistical disruption.

In parallel, accelerate adoption of advanced imaging hardware and analytics where clinical benefit is established, but pair capital investment with operational training programs to ensure efficient utilization. Engage proactively with payers and health technology assessment bodies by presenting pragmatic evidence packages and health-economic narratives that reflect real-world workflows. Foster strategic alliances across the value chain-linking developers, imaging vendors, providers, and patient advocacy groups-to create integrated value propositions that lower adoption friction. Finally, embed digital data strategies that enable longitudinal outcome tracking and real-world evidence generation; such capabilities support continuous improvement, regulatory interactions, and commercialization efforts. Together, these measures create a durable foundation for clinical impact and sustainable commercial performance.

A transparent, multi-source research approach combining primary expert interviews, peer-reviewed evidence synthesis, and iterative validation to ensure robust insights

The research underpinning these insights combined an evidence-based review of peer-reviewed literature, regulatory guidance, and publicly available clinical trial registries with structured interviews of domain experts across clinical, manufacturing, and commercial functions. Primary research included qualitative discussions with practicing nuclear medicine physicians, radiopharmacists, and imaging operations leads to capture real-world workflow considerations, adoption barriers, and technology performance trade-offs. Secondary research synthesized technical white papers, consensus guidelines, and product documentation to characterize modality capabilities and agent properties.

Findings were validated through triangulation across multiple sources and refined by iterative consultation with methodologists and subject matter experts. Data quality control measures included source cross-checking, reconciliation of conflicting inputs, and a focus on clinical utility endpoints rather than proprietary commercial metrics. The research approach prioritized transparency in methodology and reproducibility of findings to support robust decision-making by clinical leaders, manufacturers, and policymakers. Where gaps in evidence existed, the analysis identified research priorities and recommended study designs to close those gaps efficiently.

A concise synthesis of how technological innovation, operational resilience, and evidence-driven commercialization converge to shape future prostate cancer diagnostics

Advances in radiopharmaceuticals, imaging hardware, and analytic technologies are collectively elevating the role of nuclear medicine diagnostics in prostate cancer care. These developments enable more precise lesion detection, improve clinical decision-making, and open pathways for closer integration of diagnostics with therapeutic planning. At the same time, trade policy shifts and supply chain complexities underscore the need for strategic resilience and localized capabilities. The net effect is a rapidly evolving ecosystem in which technical innovation must be matched by pragmatic commercialization strategies, evidence generation, and payer engagement.

For stakeholders across the value chain, the imperative is clear: align clinical priorities with operational realities and market access strategies. By investing in robust clinical validation, securing diversified and resilient supply chains, and articulating clear value propositions to payers and providers, organizations can accelerate the translation of diagnostic innovation into improved patient outcomes. Collaboration and data-sharing across institutions will further amplify the pace of adoption and the consistency of care. Ultimately, thoughtful execution across clinical, commercial, and logistical domains will determine which innovations achieve meaningful, sustained impact in prostate cancer diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of PSMA-targeted PET imaging in early detection and staging of recurrent prostate cancer
  • 5.2. Advances in radiolabeled small molecule therapeutics improving targeted radionuclide therapy outcomes in mCRPC
  • 5.3. Deployment of next generation digital PET/CT scanners enhancing image resolution and quantitative accuracy in prostate cancer diagnostics
  • 5.4. Regulatory approval and commercialization of novel radionuclide conjugates targeting PSMA for theranostic applications in prostate cancer patients
  • 5.5. Growth of hybrid PET/MRI systems to reduce radiation exposure while improving soft tissue characterization in prostate imaging
  • 5.6. Emergence of artificial intelligence algorithms for automated interpretation and prognostic risk stratification in prostate cancer nuclear scans
  • 5.7. Increasing adoption of personalized dosimetry software for optimizing safety and efficacy of lutetium-177 radioligand therapy in clinical practice
  • 5.8. Collaborations between academic institutions and pharma companies accelerating clinical trials of novel alpha-emitting PSMA therapies in prostate cancer management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical

  • 8.1. 11C Choline
  • 8.2. 18F DcfpyL
  • 8.3. 18F Fluciclovine
  • 8.4. 68Ga Psma
  • 8.5. Emerging Agents
    • 8.5.1. 18F Psma 1007
    • 8.5.2. 64Cu Psma

9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality

  • 9.1. Pet
    • 9.1.1. Digital Pet
    • 9.1.2. Time Of Flight Pet
  • 9.2. Spect
    • 9.2.1. Conventional Spect
    • 9.2.2. Spect Ct

10. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User

  • 10.1. Academic Research Institute
  • 10.2. Diagnostic Center
  • 10.3. Hospital

11. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication

  • 11.1. Biochemical Recurrence Detection
  • 11.2. Initial Staging
  • 11.3. Treatment Monitoring

12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. GE HealthCare Technologies Inc.
    • 15.3.2. Siemens Healthineers AG
    • 15.3.3. Koninklijke Philips N.V.
    • 15.3.4. Cardinal Health, Inc.
    • 15.3.5. Bayer AG
    • 15.3.6. Lantheus Holdings, Inc.
    • 15.3.7. Bracco Imaging S.p.A.
    • 15.3.8. Telix Pharmaceuticals Limited
    • 15.3.9. Eckert & Ziegler Strahlen- und Medizintechnik AG
    • 15.3.10. Isotope Technologies Munich SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. AS